









Markets
/
Stocks
/
nasdaq-snyr
/

Synergy CHC Corp

SNYR

2.270USD

+0.100+4.61%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

21.43MMarket Cap

6.62P/E TTM



Synergy CHC Corp

2.270

+0.100+4.61%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Synergy CHC Corp

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Synergy CHC Corp's Score

Industry at a Glance

Industry Ranking

102 / 159

Overall Ranking

265 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+327.35%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Synergy CHC Corp Highlights

StrengthsRisks

Synergy CHC Corp. is a consumer healthcare and beauty company. The Company is the provider of consumer health care, beauty, and lifestyle products. The Company’s brand portfolio consists of FOCUSfactor, Flat Tummy, and HAND MD. FOCUSfactor is a brain health supplement brand. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals.

Growing

The company is in a growing phase, with the latest annual income totaling USD 34.83M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 34.83M.

Undervalued

The company’s latest PE is 7.75, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 445.99K shares, decreasing 62.28% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 22.13K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.56, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is average.

Score

Industry at a Glance

Previous score

6.56

Change



Financials

4.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.91

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.02

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.61

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.20

Key Metrics

Free cash flow

No Data

Synergy CHC Corp's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.74, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 7.75, which is 129.49% below the recent high of 17.78 and 14.70% above the recent low of 6.61.

Score

Industry at a Glance

Previous score

7.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 102/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Synergy CHC Corp is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+360.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Synergy CHC Corp

SNYR

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.12, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 2.66 and the support level at 1.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.50

Change

-0.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.036

Sell

RSI(14)

44.812

Neutral

STOCH(KDJ)(9,3,3)

17.444

Neutral

ATR(14)

0.232

Low Volatility

CCI(14)

-99.094

Neutral

Williams %R

85.109

Oversold

TRIX(12,20)

-0.194

Sell

StochRSI(14)

75.606

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.278

Sell

MA10

2.345

Sell

MA20

2.379

Sell

MA50

2.378

Sell

MA100

2.802

Sell

MA200

2.792

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gowan Private Equity, Inc.

3.68M

Knight Therapeutics (Barbados), Inc.

1.48M

Ross (Jack)

674.81K

+1.67%

Sanders Morris LLC

391.70K

+5.01%

Dunhill Distribution Group, Inc.

269.63K

Gowan Capital, Inc.

136.56K

SoRelle (James Paul)

108.96K

The Vanguard Group, Inc.

Star Investors

22.13K

XTX Markets LLC

20.13K

Geode Capital Management, L.L.C.

10.31K

+4.85%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.08, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.